Perrigo Reports Third Quarter Fiscal Year 2022 Financial Results From Continuing OperationsPRNewsWire • 11/08/22
Perrigo Announces Strategic Investment to Expand and Strengthen U.S. Manufacturing of Infant FormulaPRNewsWire • 11/01/22
Perrigo Receives Notification of Postponement for Joint FDA Advisory Committee to Review Opill® Daily Oral Contraceptive for Over-The-Counter (OTC) UsePRNewsWire • 10/26/22
PERRIGO ANNOUNCES JOINT FDA ADVISORY COMMITTEE TO REVIEW OPILL® DAILY ORAL CONTRACEPTIVE FOR OVER-THE-COUNTER (OTC) USEPRNewsWire • 09/12/22
Perrigo (PRGO) Down 8.2% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 09/08/22
Perrigo (PRGO) CEO, Murray Kessler on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/09/22
PERRIGO REPORTS SECOND QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS FROM CONTINUING OPERATIONSPRNewsWire • 08/09/22
FDA to consider pharma company's application for over-the-counter birth control pillFox Business • 07/11/22
Perrigo's HRA Pharma Submits Application to FDA for First-Ever OTC Birth Control PillPRNewsWire • 07/11/22